Spyre Therapeutics, Inc. announced that it expanded its leadership team with the appointment of Kate Tansey Chevlen as CCO. Ms. Tansey Chevlen is a seasoned biopharma commercial leader with nearly two decades of experience driving strategy, execution, and growth across U.S. and global markets at Amgen. Ms. Tansey Chevlen joins Spyre from Amgen where she most recently held the position of VP, Global Marketing Head for Immunology and Inflammation.
During her time at Amgen, she has held senior leadership roles across marketing, sales, and market access, and has played a pivotal role in multiple successful product launches. Ms. Tansey Chevlen has been instrumental in shaping as well as implementing go-to-market and patient access strategies, and partnering closely with cross-functional teams to translate scientific innovation into meaningful commercial impact. Ms. Tansey Chevlen holds a BA in Politics from Brandeis University and an MBA from the Johnson Graduate School of Management at Cornell University.
